Apixio Series D preferred stock by SSM Partners
$19,250,000
First Analysis acted as the exclusive placement agent in a $19.3 million growth capital raise for Apixio Inc. – a leader in cognitive computing applications to uncover and make accessible the knowledge from clinical data for optimal healthcare decision-making. First Analysis provided advisory expertise to Apixio throughout the transaction, including preparation, positioning, investor coordination and contact, due diligence and negotiation.
About Apixio:
Headquartered in San Mateo, Calif. and powered by its cognitive computing platform, Apixio brings advanced data to healthcare by extracting and analyzing previously trapped unstructured medical record data, giving healthcare payers and providers unprecedented access to groundbreaking insights. The Company’s computing platform is built upon the insights from analyzing more than six million patient charts. Apixio’s HCC Profiler Solution mines medical charts and Medicare-reported chronic condition data to help its customers compute patient risk scores more efficiently and accurately than they could with traditional chart review methods. It also enables more targeted care delivery and helps Medicare set payor and provider payment for patients enrolled in Medicare Advantage (MA), powering more cost-effective, high-quality care.
About SSM Partners:
SSM has been partnering with talented entrepreneurs for more than 20 years. The firm invests in rapidly growing, technology-enabled companies in the software & technology, internet & consumer and heathcare services & IT industries. SSM companies have differentiated and proven business models, large market opportunities, and the ability to generate high returns on invested capital. Starting with a relationship built on trust, SSM offers its entrepreneur-partners a thorough understanding of the growth company lifecycle and a patient approach to building great businesses.